share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144:擬議出售證券
美股SEC公告 ·  2024/11/05 05:44

Moomoo AI 已提取核心訊息

Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 13,871 shares of common stock on November 4, 2024. The shares, valued at an aggregate market value of $120,459, were acquired by Watanabe on November 1, 2024, through a restricted stock vest from Arcutis Biotherapeutics. This transaction follows a period where no other securities were sold by Watanabe in the past three months, as per the provided transaction history.
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 13,871 shares of common stock on November 4, 2024. The shares, valued at an aggregate market value of $120,459, were acquired by Watanabe on November 1, 2024, through a restricted stock vest from Arcutis Biotherapeutics. This transaction follows a period where no other securities were sold by Watanabe in the past three months, as per the provided transaction history.
arcutis biotherapeutics公司高管Todd Franklin Watanabe計劃於2024年11月4日出售13,871股普通股。這些股份的市值總額爲120,459美元,是Watanabe於2024年11月1日通過arcutis biotherapeutics的限制性股票授予獲得的。根據提供的交易歷史記錄,此次交易是在過去三個月中Watanabe未賣出其他證券之後進行的。
arcutis biotherapeutics公司高管Todd Franklin Watanabe計劃於2024年11月4日出售13,871股普通股。這些股份的市值總額爲120,459美元,是Watanabe於2024年11月1日通過arcutis biotherapeutics的限制性股票授予獲得的。根據提供的交易歷史記錄,此次交易是在過去三個月中Watanabe未賣出其他證券之後進行的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息